EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study

Khinh Ranh Voong, Peter B Illei, Bradley Presson, Dipika Singh, Zhen Zeng, Mara Lanis, Russell K Hales, Chen Hu, Phuoc T Tran, Christos Georgiades, Cheng Ting Lin, Jeffrey Thiboutout und 5 weitere

Journal for ImmunoTherapy of Cancer · 2023-10 · 11 (10) · e007188

DOI: 10.1136/jitc-2023-007188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.10.2023. Verfasst von Khinh Ranh Voong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA kvoong1@jh.edu ksmit228@jhmi.edu. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, The Mark Foundation for Cancer Research, Bloomberg-Kimmel Institute for Cancer Immunotherapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stereotactic ablative body radiation (SABR) delivers high rates of local control in early-stage non-small cell lung cancer (NSCLC); however, systemic immune effects are poorly understood. Here, we evaluate the early pathologic and immunologic effects of SABR. Blood/core-needle tumor biopsies were collected from six patients with stage I NSCLC before and 5–7 days after SABR (48 Gy/4 or 50 Gy/5 fractions). Serial blood was collected up to 1-year post-SABR. We used immunohistochemistry to evaluate pathological changes, immune-cell populations (CD8, FoxP3), and PD-L1/PD-1 expression within the tumor. We evaluated T-cell receptor (TCR) profile changes in the tumor using TCR sequencing. We used the MANAFEST (Mutation-Associated Neoantigen Functional Expansion of Specific T-cells) assay to detect peripheral neoantigen-specific T-cell responses and dynamics. At a median follow-up of 40 months, 83% of patients (n=5) were alive without tumor progression. Early post-SABR biopsies showed viable tumor and similar distribution of immune-cell populations as compared with baseline samples. Core-needle samples proved insufficient to detect population-level TCR-repertoire changes. Functionally, neoantigen-specific T-cells were detected in the blood prior to SABR. A subset of these patients had a transient increase in the frequency of neoantigen-specific T-cells between 1 week and 3–6 months after SABR. SABR alone could induce a delayed, transient neoantigen-specific T-cell immunologic response in patients with stage I NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaHumansProspective StudiesTreatment OutcomeReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CD8-positive T-lymphocytesadaptive immunitynon-small cell lung cancerradiotherapy

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA kvoong1@jh.edu ksmit228@jhmi.edu.
  • Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA.
  • The Mark Foundation Center for Advanced Genomics and Imaging, Baltimore, Maryland, USA.
  • Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA.

Förderung

  • NCI NIH HHS
  • The Mark Foundation for Cancer Research
  • Bloomberg-Kimmel Institute for Cancer Immunotherapy
  • American Lung Association
  • Institute for Cancer Immunotherapy
  • Commonwealth Foundation
  • The Mark Foundation Center for Advanced Genomics and Imaging
  • Lung Cancer Research Foundation

Zitieren

APA

Voong, K. R., Illei, P. B., Presson, B., Singh, D., Zeng, Z., Lanis, M., Hales, R. K., Hu, C., Tran, P. T., Georgiades, C., Lin, C. T., Thiboutout, J., Brahmer, J. R., Forde, P. M., Naidoo, J., Anagnostou, V., & Smith, K. N. (2023). Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study. Journal for ImmunoTherapy of Cancer, 11(10), e007188. https://doi.org/10.1136/jitc-2023-007188

Vancouver

Voong KR, Illei PB, Presson B, Singh D, Zeng Z, Lanis M, et al. Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007188. doi:10.1136/jitc-2023-007188

BibTeX
@article{Voong2023,
  author = {Voong, Khinh Ranh and Illei, Peter B and Presson, Bradley and Singh, Dipika and Zeng, Zhen and Lanis, Mara and Hales, Russell K and Hu, Chen and Tran, Phuoc T and Georgiades, Christos and Lin, Cheng Ting and Thiboutout, Jeffrey and Brahmer, Julie R and Forde, Patrick M and Naidoo, Jarushka and Anagnostou, Valsamo and Smith, Kellie N},
  title = {Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {e007188},
  doi = {10.1136/jitc-2023-007188}
}
Kostenlos starten →